10.25384/SAGE.7076786.v1
Peter A. Patriarca
Peter A.
Patriarca
R. Michael Van Auken
R. Michael
Van Auken
Scott A. Kebschull
Scott A.
Kebschull
Supplemental Material, Risk-Benefit_Manuscript_revised_supporting_material_20171025a_w_tables2 - Analysis of the Risks and Benefits of New Chemical Entities Approved by the US Food and Drug Administration (FDA) and Subsequently Withdrawn From the US Market
SAGE Journals
2018
drug
risk
benefit
regulatory decision making
2018-01-10 12:00:00
Journal contribution
https://sage.figshare.com/articles/journal_contribution/Supplemental_Material_Risk-Benefit_Manuscript_revised_supporting_material_20171025a_w_tables2_-_Analysis_of_the_Risks_and_Benefits_of_New_Chemical_Entities_Approved_by_the_US_Food_and_Drug_Administration_FDA_and_Subsequently_Withdrawn_From_the_US_Market/7076786
<p>Supplemental Material, Risk-Benefit_Manuscript_revised_supporting_material_20171025a_w_tables2 for Analysis of the Risks and Benefits of New Chemical Entities Approved by the US Food and Drug Administration (FDA) and Subsequently Withdrawn From the US Market by Peter A. Patriarca, R. Michael Van Auken, and Scott A. Kebschull in Therapeutic Innovation & Regulatory Science</p>